Rani Therapeutics (NASDAQ:RANI) PT Raised to $13.00

Rani Therapeutics (NASDAQ:RANI) had its target price increased by equities research analysts at HC Wainwright from $12.00 to $13.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 81.82% from the company’s current price.

RANI has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Rani Therapeutics in a research report on Tuesday, February 6th. Canaccord Genuity Group dropped their price objective on Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 27th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $11.75.

Rani Therapeutics Trading Down 4.2 %

RANI opened at $7.15 on Tuesday. The firm’s 50 day moving average is $4.65 and its 200-day moving average is $3.51. Rani Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.75. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.96. The firm has a market capitalization of $358.64 million, a P/E ratio of -5.56 and a beta of 0.33.

Rani Therapeutics (NASDAQ:RANI) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. Analysts expect that Rani Therapeutics will post -0.94 EPS for the current fiscal year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.